Staging of bladder cancer

Martin J. Magers, Antonio Lopez-Beltran, Rodolfo Montironi, Sean R. Williamson, Hristos Kaimakliotis, Liang Cheng

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Urothelial carcinoma of the urinary bladder is a heterogeneous disease with multiple possible treatment modalities and a wide spectrum of clinical outcome. Treatment decisions and prognostic expectations hinge on accurate and precise staging, and the recently published American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition, should be the basis for staging of urinary bladder tumours. It is unfortunate that the International Union Against Cancer (UICC) 8th edition failed to incorporate new data which is considered in the AJCC 8th edition. Thus, the AJCC 8th edition is the focus of this review. Several critical changes and clarifications are made by the AJCC 8th edition relative to the 7th edition. Although the most obvious changes in the 8th edition are in the N (i.e. perivesical lymph node involvement now classified as N1) and M (i.e. M1 is subdivided into M1a and M1b) categories, several points are clarified in the T category (e.g. substaging of pT1 should be attempted). Further optimisation, however, is required. No particular method of substaging pT1 is formally recommended. In this review, these modifications are discussed, as well as points, which require further study and optimisation.

Original languageEnglish (US)
Pages (from-to)112-134
Number of pages23
JournalHistopathology
Volume74
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Urinary Bladder Neoplasms
Urinary Bladder
Neoplasms
Neoplasm Staging
Lymph Nodes
Carcinoma

Keywords

  • metastasis
  • prognosis
  • staging classification
  • T1 substaging
  • urinary bladder
  • urothelial carcinoma/neoplasia

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

Magers, M. J., Lopez-Beltran, A., Montironi, R., Williamson, S. R., Kaimakliotis, H., & Cheng, L. (2019). Staging of bladder cancer. Histopathology, 74(1), 112-134. https://doi.org/10.1111/his.13734

Staging of bladder cancer. / Magers, Martin J.; Lopez-Beltran, Antonio; Montironi, Rodolfo; Williamson, Sean R.; Kaimakliotis, Hristos; Cheng, Liang.

In: Histopathology, Vol. 74, No. 1, 01.01.2019, p. 112-134.

Research output: Contribution to journalReview article

Magers, MJ, Lopez-Beltran, A, Montironi, R, Williamson, SR, Kaimakliotis, H & Cheng, L 2019, 'Staging of bladder cancer', Histopathology, vol. 74, no. 1, pp. 112-134. https://doi.org/10.1111/his.13734
Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis H, Cheng L. Staging of bladder cancer. Histopathology. 2019 Jan 1;74(1):112-134. https://doi.org/10.1111/his.13734
Magers, Martin J. ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Williamson, Sean R. ; Kaimakliotis, Hristos ; Cheng, Liang. / Staging of bladder cancer. In: Histopathology. 2019 ; Vol. 74, No. 1. pp. 112-134.
@article{bd7b841537bd42999557788e816e80bc,
title = "Staging of bladder cancer",
abstract = "Urothelial carcinoma of the urinary bladder is a heterogeneous disease with multiple possible treatment modalities and a wide spectrum of clinical outcome. Treatment decisions and prognostic expectations hinge on accurate and precise staging, and the recently published American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition, should be the basis for staging of urinary bladder tumours. It is unfortunate that the International Union Against Cancer (UICC) 8th edition failed to incorporate new data which is considered in the AJCC 8th edition. Thus, the AJCC 8th edition is the focus of this review. Several critical changes and clarifications are made by the AJCC 8th edition relative to the 7th edition. Although the most obvious changes in the 8th edition are in the N (i.e. perivesical lymph node involvement now classified as N1) and M (i.e. M1 is subdivided into M1a and M1b) categories, several points are clarified in the T category (e.g. substaging of pT1 should be attempted). Further optimisation, however, is required. No particular method of substaging pT1 is formally recommended. In this review, these modifications are discussed, as well as points, which require further study and optimisation.",
keywords = "metastasis, prognosis, staging classification, T1 substaging, urinary bladder, urothelial carcinoma/neoplasia",
author = "Magers, {Martin J.} and Antonio Lopez-Beltran and Rodolfo Montironi and Williamson, {Sean R.} and Hristos Kaimakliotis and Liang Cheng",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/his.13734",
language = "English (US)",
volume = "74",
pages = "112--134",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Staging of bladder cancer

AU - Magers, Martin J.

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Williamson, Sean R.

AU - Kaimakliotis, Hristos

AU - Cheng, Liang

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Urothelial carcinoma of the urinary bladder is a heterogeneous disease with multiple possible treatment modalities and a wide spectrum of clinical outcome. Treatment decisions and prognostic expectations hinge on accurate and precise staging, and the recently published American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition, should be the basis for staging of urinary bladder tumours. It is unfortunate that the International Union Against Cancer (UICC) 8th edition failed to incorporate new data which is considered in the AJCC 8th edition. Thus, the AJCC 8th edition is the focus of this review. Several critical changes and clarifications are made by the AJCC 8th edition relative to the 7th edition. Although the most obvious changes in the 8th edition are in the N (i.e. perivesical lymph node involvement now classified as N1) and M (i.e. M1 is subdivided into M1a and M1b) categories, several points are clarified in the T category (e.g. substaging of pT1 should be attempted). Further optimisation, however, is required. No particular method of substaging pT1 is formally recommended. In this review, these modifications are discussed, as well as points, which require further study and optimisation.

AB - Urothelial carcinoma of the urinary bladder is a heterogeneous disease with multiple possible treatment modalities and a wide spectrum of clinical outcome. Treatment decisions and prognostic expectations hinge on accurate and precise staging, and the recently published American Joint Committee on Cancer (AJCC) Staging Manual, 8th edition, should be the basis for staging of urinary bladder tumours. It is unfortunate that the International Union Against Cancer (UICC) 8th edition failed to incorporate new data which is considered in the AJCC 8th edition. Thus, the AJCC 8th edition is the focus of this review. Several critical changes and clarifications are made by the AJCC 8th edition relative to the 7th edition. Although the most obvious changes in the 8th edition are in the N (i.e. perivesical lymph node involvement now classified as N1) and M (i.e. M1 is subdivided into M1a and M1b) categories, several points are clarified in the T category (e.g. substaging of pT1 should be attempted). Further optimisation, however, is required. No particular method of substaging pT1 is formally recommended. In this review, these modifications are discussed, as well as points, which require further study and optimisation.

KW - metastasis

KW - prognosis

KW - staging classification

KW - T1 substaging

KW - urinary bladder

KW - urothelial carcinoma/neoplasia

UR - http://www.scopus.com/inward/record.url?scp=85058713538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058713538&partnerID=8YFLogxK

U2 - 10.1111/his.13734

DO - 10.1111/his.13734

M3 - Review article

C2 - 30565300

AN - SCOPUS:85058713538

VL - 74

SP - 112

EP - 134

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -